CHCWM – Cancer & Hematology Centers of West Michigan

CA115-001 (Bristol Myers Squibb)

CA115-001 (Bristol Myers Squibb)

 Description:   Phase 1b/2 Study of BMS-986442 in Combination with Nivolumab or Nivolumab and Chemotherapies in Participants with Advanced Solid Tumors and Non-small cell Lung Cancer

Mechanism of Action:  Bispecific antibody TIGIT and CD96

Target Patient Population: Starting with dose escalation in advanced solid tumors with specific cohorts in combination with Nivolumab

Study Design:  Study Drug will be administered IV every 3 weeks